Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rad51-IN-2,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CYT-0851, its investigational monocarboxylate transporter inhibitor, which is investigated combination study with capecitabine or gemcitabine in advanced ovarian cancer and other solid tumors.
Product Name : CYT-0851
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2023
Lead Product(s) : Rad51-IN-2,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rad51-IN-2,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
Details : CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Product is being investigation in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
Product Name : CYT-0851
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : Rad51-IN-2,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rad51-IN-2,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CYT-0851 is in a Phase 1/2 clinical trial as both a monotherapy and in combination with standard of care chemotherapy and has the potential to be a first-in-class MCT inhibitor. By impairing monocarboxylate transporter-mediated lactate transport, CYT-085...
Product Name : CYT-0851
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Rad51-IN-2,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rad51-IN-2,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data for CYT-0851 show that the drug has performed well in cancer patients: it has desirable pharmacologic properties with an estimated half-life of three days, dose proportional exposure, and a dose dependent, predictable, and favorable safety profile.
Product Name : CYT-0851
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2022
Lead Product(s) : Rad51-IN-2,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rad51-IN-2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $80.0 million
Deal Type : Series C Financing
Details : Proceeds will support monotherapy and combination therapy trials of first-in-class RAD51 inhibitor CYT-0851, as well as fund R&D for novel synthetic lethal cancer targets.
Product Name : CYT-0851
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 02, 2021
Lead Product(s) : Rad51-IN-2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $80.0 million
Deal Type : Series C Financing
Lead Product(s) : Rad51-IN-2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 study will evaluate the safety and tolerability of CYT-0851 as monotherapy and identify the recommended dose for phase 2 and future studies.
Product Name : CYT-0851
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : Rad51-IN-2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable